| Trial ID: | L0524 |
| Source ID: | IRCT2017073135415N1
|
| Associated Drug: |
Dava AL-balgham
|
| Title: |
Evaluation of the effect of Dava AL-balgham,on serum levels of liver enzymes in patients with NAFLD.
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Fatty liver desease. <br>Nonalcoholic fatty liver disease (NAFLD);Nonalcoholic fatty liver disease (NAFLD)
|
| Interventions: |
Intervention 1: The case group receives Dava Al-balgham tablets two pills with each meal, for three months. Intervention 2: The control group receives cellulose tablets in two tablets each serving for three months.;Treatment - Drugs;Treatment - Drugs;The
|
| Outcome Measures: |
Ast. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.;Alt. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.;Alkp. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.Crt. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;BUN. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;PT. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;PTT. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;INR. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: U / L, Spectrophotometer.;Level of quality of life. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Questionnaire 36 questions.;BMI. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Weight/(height(meter))2 Kg/m2.;WHR. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Waist to hip circumference Cm/cm.;Blood presure. Timepoint: At the beginning of the intervention, three months after taking the medication or placebo. Method of measurement: Mercury pressure meter mmHg.
|
| Sponsor/Collaborators: |
Vice chancellor for research, Qom University of Medical Sciences
|
| Gender: |
All
|
| Age: |
17 years64 years
|
| Phases: |
Not applicable
|
| Enrollment: |
100
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: By using the available sampling method, individuals with entry and failure criteria will be included in the study, then tr
|
| Start Date: |
17/09/2017
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/26767
|
